BioNeutral is Committed to Increasing Shareholder Value.
Innovation That Drives Profitability and Shareholder Value
As a publicly traded company (OTC/BB: "BONU"), BioNeutral Group is completely committed to resarch, development, commercialization and marketing of innovative products that serve the infection control community and drive steady growth to the bottom line. BioNeutral takes a conservative approach to creating, increasing and protecting shareholder value through careful and well-controlled execution of our operational, development and marketing programs.
We Really Want to Hear From You
Our shareholders are essential to our success. At BioNeutral, we believe in accurate, open and complete representation of the Company's status and milestones. Dialog with our investor base is a critical component of building a strong company. Current and prospective investors are strongly encoruaged to contact us at any time for further information, to obtain the latest reports, and discuss investment opportunities. We look forward to hearing from you.
How To Contact BioNeutral Group
We are committed to prompt response to all investor-related inquiries. For easiest communication, please simply clik the 'Contact Us' link at the top of this page. If you have an urgent requirement, please do not hesitate to contact us directly at:
2013 Stockholders Letter: download
2012 Q3 Form 10-Q – XBRL: download